Risk-Adapted Therapy Improves Survival in Pediatric Acute Myeloid Leukemia

The clinical management of pediatric acute myeloid leukemia (AML) has increasingly shifted toward precision medicine, driven by an evolving understanding of the disease's genetic landscape and the integration of molecular biomarkers [1, 2, 3]. While intensive chemotherapy remains the backbone of treatment, the ability to accurately identify which children require treatment escalation, such as allogeneic hematopoietic stem cell transplantation (the replacement of a patient's hematopoietic system with healthy donor cells), is critical for balancing curative intent with the risk of therapy-related toxicity [4, 5]. Central to this effort is the monitoring of measurable residual disease (a highly sensitive technique using flow cytometry or molecular assays to detect sub-microscopic levels of leukemia cells), which has emerged as a primary independent prognostic indicator [6, 7]. In a recent analysis of 136 pediatric patients, a reduction of less than 3-log in transcript levels after induction chemotherapy predicted an inferior prognosis (p < 0.05), reinforcing the need for early response-based intervention [7]. Despite these advances, optimizing induction agents and refining thresholds for risk-adapted consolidation remain active areas of clinical investigation [8, 9]. Findings from the AIEOP-AML-2013 trial involving 371 patients demonstrated that integrated genetic and response-based stratification achieved a morphological complete remission rate of 92%, highlighting the efficacy of contemporary risk-stratified protocols [10].